122 related articles for article (PubMed ID: 27925025)
21. [Challenges of lopinavir/ritonavir in the chronicity of human immunodeficiency virus infection].
Aguirrebengoa K
Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():26-30. PubMed ID: 25542873
[TBL] [Abstract][Full Text] [Related]
22. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
[TBL] [Abstract][Full Text] [Related]
23. Affordability of adult HIV/AIDS treatment in developing countries: modelling price determinants for a better insight of the market functioning.
Sagaon-Teyssier L; Singh S; Dongmo-Nguimfack B; Moatti JP
J Int AIDS Soc; 2016; 19(1):20619. PubMed ID: 27765142
[TBL] [Abstract][Full Text] [Related]
24. An exploration of compulsory licensing as an effective policy tool for antiretroviral drugs in India.
Jain D; Darrow JJ
Health Matrix Clevel; 2013; 23(2):425-57. PubMed ID: 24341078
[TBL] [Abstract][Full Text] [Related]
25. Secondary patenting of branded pharmaceuticals: a case study of how patents on two HIV drugs could be extended for decades.
Amin T; Kesselheim AS
Health Aff (Millwood); 2012 Oct; 31(10):2286-94. PubMed ID: 23048110
[TBL] [Abstract][Full Text] [Related]
26. Brazil and USA at loggerheads over production of generic antiretrovirals.
Ahmad K
Lancet; 2001 Feb; 357(9254):453. PubMed ID: 11273079
[No Abstract] [Full Text] [Related]
27. [Lack of bioavailability of generic lopinavir/ritonavir not prequalified by WHO marketed in Africa (Congo Brazzaville)].
Camara S; Zucman D; Vasse M; Goudjo A; Guillard E; Peytavin G
Bull Soc Pathol Exot; 2015 Feb; 108(1):46-8. PubMed ID: 25256250
[TBL] [Abstract][Full Text] [Related]
28. Compulsory licensing in Canada and Thailand: comparing regimes to ensure legitimate use of the WTO rules.
Lybecker KM; Fowler E
J Law Med Ethics; 2009; 37(2):222-39. PubMed ID: 19493068
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection.
Simpson KN; Luo MP; Chumney E; Sun E; Brun S; Ashraf T
HIV Clin Trials; 2004; 5(5):294-304. PubMed ID: 15562370
[TBL] [Abstract][Full Text] [Related]
30. [Positioning of lopinavir/ritonavir in antiretroviral treatment schemes].
Camacho Á; Rivero A
Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():31-4. PubMed ID: 25542874
[TBL] [Abstract][Full Text] [Related]
31. The role of civil society in protecting public health over commercial interests: lessons from Thailand.
Ford N; Wilson D; Bunjumnong O; von Schoen Angerer T
Lancet; 2004 Feb; 363(9408):560-3. PubMed ID: 14975620
[No Abstract] [Full Text] [Related]
32. Making tenofovir accessible in the brazilian public health system: patent conflicts and generic production.
Veras J
Dev World Bioeth; 2014 Aug; 14(2):92-100. PubMed ID: 24889312
[TBL] [Abstract][Full Text] [Related]
33. [The patent legislation in India fails the HIV/AIDS work].
Holen Ø
Tidsskr Nor Laegeforen; 2005 Oct; 125(19):2666-7. PubMed ID: 16215618
[No Abstract] [Full Text] [Related]
34. The (political) economics of antiretroviral treatment in developing countries.
Nattrass NJ
Trends Microbiol; 2008 Dec; 16(12):574-9. PubMed ID: 18964022
[TBL] [Abstract][Full Text] [Related]
35. The Brazilian experiment: HIV drugs for all.
Flaer PJ; Younis MZ
J Health Care Finance; 2009; 36(2):90-6. PubMed ID: 20499725
[TBL] [Abstract][Full Text] [Related]
36. Compulsory pharmaceutical patent licensing in Brazil: the controversy of public interest.
Rodrigues da Silva C; Galvão de Botton L
Pharm Pat Anal; 2013 Nov; 2(6):685-7. PubMed ID: 24237232
[No Abstract] [Full Text] [Related]
37. Thailand court forces reversal of drug firm antiretroviral patent.
Ahmad K
Lancet; 2002 Oct; 360(9341):1231. PubMed ID: 12401263
[No Abstract] [Full Text] [Related]
38. Pharmacokinetics and 48-week safety and efficacy of generic lopinavir/ritonavir in Thai HIV-infected patients.
Ramautarsing RA; van der Lugt J; Gorowara M; Sophonphan J; Ananworanich J; Lange JM; Burger DM; Phanuphak P; Ruxthungtham K; Avihingsanon A
Antivir Ther; 2013; 18(2):249-52. PubMed ID: 22908131
[TBL] [Abstract][Full Text] [Related]
39. Backlash over ritonavir price hike.
Huff B
BETA; 2004; 16(4):15-7. PubMed ID: 15386839
[TBL] [Abstract][Full Text] [Related]
40. India: New patent law may restrict access to HIV/AIDS treatments.
Cruess G
HIV AIDS Policy Law Rev; 2005 Aug; 10(2):28-30. PubMed ID: 16365971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
